TESARO (TSRO) announced that it has entered into a clinical collaboration with Genentech, a member of the Roche Group (RHHBY), to evaluate the combination of the PD-L1 antibody atezolizumab, the MEK inhibitor cobimetinib and TESARO’s PARP inhibitor ZEJULA in patients with platinum-sensitive ovarian cancer. TESARO and Genentech are also working together to evaluate the combination of ZEJULA and atezolizumab in patients with metastatic bladder cancer as a part of MORPHEUS, Roche’s novel cancer immunotherapy development platform. MORPHEUS is a Phase 1b/2 adaptive platform to develop combinations of cancer immunotherapies more rapidly and efficiently. The planned trial will be conducted by Genentech and is expected to begin by the end of 2018. TECENTRIQ and COTELLIC are registered trademarks of Genentech, a member of the Roche Group
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.